InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,584.54
(
-0.88%
)
US TECH 100
19,682.40
(
-2.17%
)
Dow Jones
39,753.75
(
0.08%
)
Brent Oil
85.11
(
0.07%
)
Bitcoin
57,282.51
(
-0.82%
)
Post# of 10489
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

PHILTSENG

Send PM Follow Ignore
Followers 4
Posts 732
Boards Moderated 0
Alias Born 09/10/2013

PHILTSENG

Re: None

Tuesday, 01/14/2014 11:40:00 AM

Tuesday, January 14, 2014 11:40:00 AM

Post# of 10489
Piper Jaffray is raising its price target on Galena Biopharma to $7 from $2.75, citing an increased forecast for sales of Abstral, which Galena acquired in March and launched in October. Piper raised its Abstral sales forecast for 2014 to $16.5M from $10M, a run-rate at which the firm says the Abstral business could turn a profit, and the firm maintains an Overweight rating on shares.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up